Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the virtual Improvate Life-Saving Technologies International Conference 2021 being held on Thursday, July 22, 2021. During the interview, which will take place at approximately 5:15 AM EDT (12:15 PM Israel time), Dr. Hershkovitz will discuss the Company’s AllocetraTM macrophage reprogramming cell therapy platform, which is being developed for life-threatening unmet medical conditions, and the Company’s current development plans. 

By A Silva